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In 2016, WHO recommended that Dengvaxia, the first dengue vaccine, licensed for use in 
those aged 9 years or above, be considered for use in highly endemic regions where at least 
70% of 9-year old children had been previously infected with dengue. The Philippines was 
the first country to introduce Dengvaxia on a large scale, in selected highly endemic regions 
targeting about 1 million children aged 9-10 years. In November 2017, Sanofi Pasteur 
reported an excess risk of hospitalized and severe dengue in vaccinees who had not had a 
previous dengue infection at the time of vaccination, based on retrospective analyses of data 
from the Dengvaxia Phase 3 trials, using a novel NS1 based antibody assay.1 Following this 
report, the Philippine Dengvaxia programme was suspended.  By then, over 830, 000 children 
had received at least 1 out of 3 recommended Dengvaxia doses. The news about the safety 
concerns in dengue naive vaccinees led to a major public outcry, with loss in vaccine 
confidence that extended to routine childhood vaccines.2   
 
Parents whose children had received Dengvaxia were understandably alarmed by the reported 
adverse effect of the vaccine, as most parents will not have known whether or not their child 
had had a previous dengue infection, and any cases of severe dengue in vaccinees may have 
been attributed to the vaccine. Similarly, clinicians looking after vaccinated children admitted 
with severe dengue will also be tempted to attribute that episode to vaccine-enhanced disease. 
In reality, however, a minority of cases may be so attributable. 
 
No vaccine is 100% efficacious and cases of breakthrough disease arise through vaccine 
failure. For the first licensed dengue vaccine, the issues of efficacy and safety are complex as 
both are driven by serostatus. Serostatus refers to whether a person had a previous dengue 
infection; seropositive persons had at least one dengue infections in the past, whereas 
seronegative persons are dengue-naïve. The efficacy of Dengvaxia against severe dengue in 
seropositive vaccinees in the Phase 3 trials was 84% (95% CI 63% to 93%).1 The vast 
majority, possibly around 85%, of all vaccinees in the Philippines programme were likely 
seropositive.3 Hence, we would expect to see breakthrough disease in seropositive vaccinees 
when exposed to natural infection, especially in light of the current outbreak of dengue in the 
Philippines. Cases of severe dengue following vaccination would be a mixture of 
breakthrough disease in seropositive vaccinees and enhanced disease in seronegative children.  
 
It is important that the risks associated with Dengvaxia are put in an appropriate perspective.  
Firstly, many cases of hospitalised and severe dengue following vaccination are likely to be 
attributable to vaccine breakthrough cases in seropositive vaccinees, as a high proportion of 
vaccinees are likely to have been dengue seropositive, among whom the vaccine protects but 
does not give total protection. Secondly, among all children vaccinated, the overall incidence 
of hospitalised dengue is likely to be substantially lower in the 5 years following vaccination 
than would have been the case had no one been vaccinated.4 On a population level, in highly 
endemic regions like those vaccinated in the Philippines, the number of dengue cases averted 
by the Dengvaxia substantially outweigh the number of vaccine-induced cases, and there is an 
overall net benefit to the population. Of course, vaccinating only those testing seropositive 
would be the preferred strategy for future use of the vaccine, but this depends on the 
development of sensitive and specific rapid point-of-care tests to identify this group.5 
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